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Background: Hepatocytes and stem cells transplantation may be an alternative to liver transplantation in acute or
chronic liver disease. We aimed to evaluate the therapeutic potential of mesenchymal stem cells from human umbilical
cord (UCMSCs), a readily available source of mesenchymal stem cells, in the CCl4-induced acute liver injury model.
Methods: Mesenchymal stem cells profile was analyzed by flow cytometry. In order to evaluate the capability of our
UCMSCs to differentiate in hepatocytes, cells were seeded on three different supports, untreated plastic support,
MatrigelTM and human liver acellular matrix. Cells were analyzed by immunocitochemistry for alpha-fetoprotein and
albumin expression, qPCR for hepatocyte markers gene expression, Periodic Acid-Schiff staining for glycogen storage,
ELISA for albumin detection and colorimetric assay for urea secretion.
To assess the effects of undifferentiated UCMSCs in hepatic regeneration after an acute liver injury, we transplanted
them via tail vein in mice injected intraperitoneally with a single dose of CCl4. Livers were analyzed by histological
evaluation for damage quantification, immunostaining for Kupffer and stellate cells/liver myofibroblasts activation and
for UCMSCs homing. Pro- and anti-inflammatory cytokines gene expression was evaluated by qPCR analysis and
antioxidant enzyme activity was measured by catalase quantification.
Data were analyzed by Mann–Whitney U-test, Kruskal-Wallis test and Cuzick’s test followed by Bonferroni correction for
multiple comparisons.
Results: We have standardized the isolation procedure to obtain a cell population with hepatogenic properties prior to
in vivo transplantation. When subjected to hepatogenic differentiation on untreated plastic support, UCMSCs
differentiated in hepatocyte-like cells as demonstrated by their morphology, progressive up-regulation of mature
hepatocyte markers, glycogen storage, albumin and urea secretion. However, cells seeded on 3D-supports showed a
minor or negligible differentiation capacity.
UCMSCs-transplanted mice showed a more rapid damage resolution, as shown by histological analysis, with a lower
inflammation level and an increased catalase activity compared to CCl4-treated mice.
Conclusions: Our findings show that UCMSCs can be reliably isolated, have hepatogenic properties and following
systemic administration are able to accelerate the resolution of an acute liver injury without any differentiation and
manipulation. These features make UCMSCs strong candidates for future application in regenerative medicine for
human acute liver disease.
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Transplantation is the gold standard procedure for treat-
ing acute and chronic end-stage liver disease [1], but the
shortage of available organs makes it mandatory to seek
alternative therapeutic strategies. Replacing diseased
hepatocytes and stimulating endogenous and exogenous
regeneration by stem cells represent the main aims of
liver-oriented cell therapy [2,3].
Recent developments in stem cell technology have
raised the hopes of identifying new expandable sources
of liver cells for use in regenerative medicine [4] and
prompted studies on the best support for their growth.
Embryonic stem cells can be considered the best model
of multipotency, but their use is limited due to legal
issues, in Italy at least (L. n. 40/2004), as well as safety
and ethical concerns [5]. Adult stem cells have conse-
quently been widely explored in recent years as a more
acceptable source of cells, including the mesenchymal
stem cells (MSCs), a population of multipotent progeni-
tors capable of differentiating towards adipogenic, osteo-
genic [6], and hepatogenic lineages [7,8] with a low
immunogenicity [9]. Therefore this cell population is
considered to be a promising candidate for novel cell-
based therapeutic strategies [10].
Bone marrow is considered the main source of MSCs
[11], but their number decreases significantly with age
[12,13] and this has led to the evaluation of alternative
sources such as adipose tissue [14] and embryo-derived
tissues, e.g. placenta [15], amniotic fluid [16], umbilical
cord blood (UCB) [17] and umbilical cord (UC) [18].
UC cells obtained from the sub-endothelial layer of
the umbilical vein can differentiate in vitro into adipo-
cytes and osteoblasts [19,20], and - when isolated from
umbilical cord jelly - they can also differentiate in vitro
and in vivo into a myogenic lineage, as previously
reported by our group [21], confirming the presence of
plasticity in this population of foetal-derived tissues.
MSC transplantation has been explored as a new clinical
approach to repair injured tissue. Following systemic ad-
ministration MSCs are recruited in the area of ischemia or
injury, as was demonstrated in lung [22], heart [23] and
kidney [24]. So far, the possibility of using human UCMSCs
to repair acute liver damage has not been evaluated.
Therefore, the main aim of this study was to evaluate
the therapeutic potential of adult mesenchymal stem
cells from human umbilical cord (UCMSCs) in a murine
model of acute liver injury using carbon tetrachloride
(CCl4), a potent hepatotoxic chemical.
More than one protocol has been proposed to isolate
these cells without reaching a scientific agreement. It is
clearly fundamental to standardize the isolation proced-
ure to obtain an adequate cell population with hepato-
genic properties prior to performing successful in vivo
transplantation. To investigate these hepatogeniccapacities we have induced UCMSCs differentiation to-
wards hepatic lineages in vitro. Since hepatocytes are
known to lose their specific functions rapidly when cul-
tured on a conventional support [25] we sought the best
cell support for hepatogenic differentiation.
Stem cell differentiation can be stimulated by growth
factors and extracellular matrix (ECM) components are
used as a cell culture support. Using an homologous
acellular matrix derived from surgical specimens repre-
sents an interesting tissue engineering approach since
the matrix is biocompatible, contains adhesion mole-
cules and growth factors, and it is obtained from a
healthy organ [26,27] and not from hepatoma cell lines,
e.g. Matrigel™ [28].
Therefore, we induced UCMSCs hepatic differenti-
ation seeded them on MatrigelTM, human liver acellular
matrix and on classic petri dishes.
Results
UCMSCs isolation and characterization
In order to characterize UCMSCs we processed 135
samples of human UC and 98% of them gave rise to
cell colonies with fibroblastoid morphology, visible in
the culture after 2–3 weeks. Flow cytometry analysis
showed a very significant expression of typical mesen-
chymal cell markers such as CD166, CD105, CD90,
CD73 and CD29, while hematopoietic markers (CD14,
CD34, CD45, CD71 and c-kit) were weakly or not
expressed. HLA-DR was not expressed at all (Figure 1).
These results were reproducible when the Wharton
jelly fragments were seeded in presence of high glucose
DMEM and 20% FBS specific for human MSCs. More-
over, UCMSCs were able to differentiate toward adipo-
genic and osteogenic lineages (as previously reported
by our group [21]). All these results demonstrated that
the UCMSCs isolated were a novel mesenchymal stem
cell population.
Furthermore, RT-PCR evaluation on UCMSCs obtained
from newborn males (representing 53% of our samples)
showed the SRY gene expression, confirming the foetal
origin of the isolated cells, as previously reported by our
group [21].
In vitro UCMSCs hepatogenic differentiation on untreated
plastic support
In order to evaluate the capability of our UCMSCs to
differentiate in hepatocytes, cells were seeded on un-
treated plastic support up to day 28. After 14 days of
culture in differentiating medium we observed changes
in cell morphology: cell spreading was reduced and the
UCMSCs acquired a polygonal shape with a granular
cytoplasm (Figure 2A).
The expression of specific hepatic markers such as the
immature hepatoblast marker alpha-fetoprotein (AFP) and
Figure 1 UCMSCs characterization. Flow cytometry analysis of UCMSCs showed a mesenchymal phenotype. Cells were positive for typical
mesenchymal markers (CD29, CD73, CD90, CD105 and CD166) while hematopoietic markers (CD14, CD34, CD45, CD71 and c-kit) were weakly or
not expressed. HLA-DR was not expressed at all.
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cylglycerol transfer protein (MTP) and tryptophan 2–3
dioxygenase (TDO) mRNAs was assessed by qPCR. Unex-
pectedly, UCMSCs constitutively expressed the messengers
coding for hepatic markers generally attributed to mature














Figure 2 Characterization of UCMSCs cultured with
hepatogenic medium on untreated plastic support.
(A) Undifferentiated and differentiated cell morphology. After
14 days of culture in differentiating medium we observed changes
in cell morphology: cell spreading was reduced and the UCMSCs
acquired a polygonal shape with a granular cytoplasm
(B) Immunocytochemical analyses for α-fetoprotein (AFP) and
albumin in UCMSCs cultured on untreated plastic support. The
UCMSCs were cultured on petri dishes with proliferative (untreated)
or differentiating medium. AFP protein expression was undetectable
in both untreated and differentiated cells. Albumin protein was
expressed by differentiated cells after 14 days but not by untreated
cells. (C) Periodic acid-Schiff (PAS) staining for glycogen storage.
UCMSCs cultured with differentiating medium on petri dishes
displayed a positive reaction to PAS staining, revealing glycogen
storage in their cytoplasm. Untreated cells were negative for PAS
staining. Scale bar: 100 μm.In control UCMSCs hepatic markers expression
remained stable at all time points considered (day 7, 14,
21 and 28) as confirmed by the Cuzick’s trend test. Other-
wise, mRNA expression of these markers was modulated
in the presence of differentiating factors (Table 1).
In fact, the expression of AFP in differentiating condi-
tions was significantly lower than in control cells at each
time point (*p values shown in Table 1). This down-regu-
lation was significant during the time course (¥p = 0.0378
z =−2.08).
In contrast, the expression of albumin mRNA was sig-
nificantly increased at each time point (*p values
reported in Table 1) and this up-regulation was time
dependent (¥p = 0.0219 z = 2.30).
Levels of MTP mRNA were significantly up-regulated
only from the 14th day onwards and this increase was
time-dependent, as confirmed by Cuzick’s trend test
(¥p = 0.0021 z = 3.08). TDO (an enzyme belonging to the
family of oxidoreductases) mRNA expression was signifi-
cantly up-regulated at each time point in a time-
dependent manner (¥p = 0.0023 z = 3.12) (Table 1).
Immunocytochemistry performed using specific anti-
human albumin antibodies clearly demonstrated the
presence of albumin already after 14 days of differenti-
ation (while the protein was never detected in control
cells). No AFP expression was detectable in either the
differentiated or the control cells (Figure 2B).
Differentiation efficiency was also assessed in func-
tional terms. ELISA confirmed that differentiated cells
were able to secrete albumin in a time-dependent man-
ner (¥p = 0.0002; z = 3.75), as shown in Table 2.
Periodic acid-Schiff staining also showed that the
UCMSCs subjected to the hepatogenic differentiation proto-
col were able to store glycogen after 14 days of culture, while
the undifferentiated UCMSCs did not (Figure 2C).
Urea measured after 28 days of culture in hepatogenic
medium showed that cells were able to metabolize ammo-
nia [1.222 (1.134; 1.304) mM/104cells/day]. Undifferentiated
cells produced lower levels of urea [0.284 (0.273; 0.328)
mM/104cells/day]. Mann Whitney-U test showed that this
difference was statistically significant (*p=4.246x10-5).
Finally, flow cytometry analysis of the differentiated
cells demonstrated a decreased expression of the typical
MSCs markers, such as CD73, CD90 and CD105, except
CD29 and CD166, acquiring a phenotype which was
more compatible with a mature cell (Table 3).
In vitro UCMSC hepatogenic differentiation on Matrigel™
In order to test whether a biological 3D support could
influence the UCMSCs differentiation toward hepato-
cytes, cells were seeded on Matrigel™. Optical analyses
showed morphological changes after 14 days in hepato-
genic medium, as seen in the cells differentiated on un-
treated plastic support (Figure 3A).
Table 1 qPCR analysis for hepatic markers in differentiated UCMSCs
7 days *p 14 days *p 21 days *p 28 days *p ¥p
Petri dishes
AFP 0.481 0.0402 0.573 0.0377 0.358 0.0485 0.124 0.0003 0.0378
(0.472; 0.482) (0.566; 0.575) (0.357; 0.364) (0.122; 0.124) (z =−2.08)
Alb 2.652 0.0158 4.298 0.0100 5.991 0.0118 7.880 0.0076 0.0219
(2.630; 2.683) (4.276; 4.438) (5.966; 6.261) (7.718; 8.144) (z = 2.30)
MTP 1.012 NS 1.924 0.0051 3.606 0.0096 4.805 0.0007 0.0021
(1.007; 1.017) (1.910; 1.929) (3.521; 3.612) (4.741; 4.821) (z = 3.08)
TDO 7.464 0.0144 10.483 0.0098 16.111 0.0091 19.575 0.0011 0.0023
(7.380; 7.576) (10.301; 10.601) (16.040; 16.295) (19.497; 19.802) (z = 3.12)
MatrigelTM
AFP 0.719 0.0450 0.592 NS 0.638 0.0202 0.587 0.0091 NS
(0.715; 0.719) (0.591; 0.596) (0.635; 0.639) (0.583; 0.589)
Alb 0.704 0.0405 1.437 NS 1.926 NS 2.486 0.0196 0.0065
(0.701; 0.704) (1.419; 1.445) (1.895; 1.945) (2.446; 2.520) (z = 2.72)
MTP 0.789 NS 0.814 NS 2.452 0.0092 2.274 0.0091 0.0122
(0.781; 0.790) (0.813; 0.820) (2.432; 2.461) (2.258; 2.278) (z = 2.51)
TDO 1.250 NS 1.210 NS 1.269 NS 1.490 NS NS
(1.170; 1.317) (1.140; 1.374) (1.258; 1.428) (1.443; 1.594)
hLAM
AFP 0.992 NS 0.823 NS 0.778 NS 0.871 NS NS
(0.982; 0.994) (0.819; 0.829) (0.777; 0.788) (0.837; 0.876)
Alb 1.580 0.0353 0.860 NS 0.834 NS 0.788 NS NS
(1.570; 1.595) (0.859; 0.867) (0.822; 0.847) (0.786; 0.793)
MTP nd nd nd nd
TDO nd nd nd nd
*p Mann–Whitney U-test ¥p Cuzick’s trend test.
Values represent median (Q1; Q3) of 5 independent experiments. Data were analyzed using the second-derivative algorithm. For each sample, the quantity of
specific hepatic marker mRNA was expressed as n-fold the normalized amount of mRNA from undifferentiated control cells.
The Mann–Whitney U-test was used for the statistical analysis of differences between undifferentiated control cells and differentiated cells at each time points
(*p). Multiple comparisons to evaluate the changes of a single mRNA expression during the time were performed with the Cuzick’s trend test (¥p). nd: not
detected; NS: not significant.
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albumin and MTP, with the exception of TDO messen-
ger, was modulated during the differentiation process at
each time point.Table 2 Albumin secretion in differentiated UCMSCs
7 days 14 days
Petri dishes 2.135 6.565
(2.010; 2.345) (6.512; 6.642)
Matrigel 1.690 6.990
(1.627; 1.772) (6.422; 7.607)
hLAM 1.475 1.740
(1.382; 1.562) (1.677; 1.822)
¥p Cuzick’s trend test.
Values represent median (Q1; Q3) (ng/ml) of 5 independent experiments. Time trenAFP mRNA expression in UCMSCs cultured in differ-
entiating medium was significantly lower than in the
corresponding control cells, but it remained stable up to
28 days (Table 1).21 days 28 days ¥p
7.850 10.668 0.0002
(7.725; 7.925) (10.525; 10.760) (z = 3.75)
6.580 10.230 0.0010
(6.400; 6.890) (10.082; 10.407) (z = 3.28)
2.825 2.985 0.0006
(2.677; 3.117) (2.852; 3.232) (z = 3.45)
ds were evaluated using the Cuzick’s trend test.
Table 3 Characterization of UCMSCs after 28 days of
culture














Flow cytometry analysis of differentiated UCMSCs on untreated plastic support
after 28 days showed a lower expression of the typical MSC markers, such as
CD73, CD90 and CD105. CD166 was spontaneously lost in undifferentiated
cells whereas its expression was maintained in differentiated UCMSCs. CD29
expression in differentiated cells increased to reach a level comparable with
human hepatocytes [7]. Hematopoietic markers remained stable for up to















Figure 3 Characterization of UCMSCs cultured with
hepatogenic medium on Matrigel™. (A) Undifferentiated and
differentiated cell morphology. Optical analyses showed
morphological changes after 14 days in hepatogenic medium.
(B) Immunocytochemical analyses for α-fetoprotein (AFP) and
albumin of UCMSCs cultured on Matrigel™ with proliferative or
differentiating medium. AFP was never detected in either
proliferative (untreated) or differentiating medium. Albumin protein
was expressed only by differentiated cells after 14 days. (C) PAS
staining for glycogen storage. UCMSCs cultured with differentiating
medium on Matrigel™ displayed a positive reaction to PAS staining,
revealing glycogen storage in their cytoplasm. Untreated cells were
negative for PAS staining. Scale bar: 100 μm.
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pression showed a rising trend, but this up-regulation
was only significant at 28th day of differentiation.
Cuzick’s trend test showed that up-regulation were time-
dependent (¥p = 0.0065 z = 2.72).
MTP mRNA expression was significantly up-regulated
from the 21st day onwards in comparison with the con-
trol values and this increase was time-dependent
(¥p = 0.0122 z = 2.51). TDO mRNA expression remained
stable compared to control cells and also during the dif-
ferentiating process (Table 1).
As previously obtained with the untreated plastic sup-
port, immunocytochemistry analyses showed that albu-
min protein was only expressed by the differentiated
cells after 14 days and no AFP expression was detectable
in the differentiated or in control cells (Figure 3B).
Functional tests demonstrated that albumin was secreted
in the supernatants of differentiated UCMSCs cultures in a
time-dependent manner (¥p=0.0010; z =3.29), reaching
levels comparable with those of the differentiated cells
seeded on untreated plastic support (Table 2).
No glycogen storage was observed in the undifferenti-
ated cells, whereas the UCMSCs cultured with differen-
tiating medium were positive to PAS staining already
after 14 days (Figure 3C).
Urea measured after 28 days of culture in hepatogenic
medium showed that cells were able to metabolize ammo-
nia in a comparable fashion with those measured on cells
differentiated on untreated plastic support [1.197 (1.161;1.240) mM/104cells/day]. Undifferentiated cells produced
lower levels of urea [0.292 (0.257; 0.309) mM/104cells/day].
Mann Whitney-U test showed that this difference was sta-
tistically significant (*p=2.538x10-5).
In vitro UCMSCs hepatogenic differentiation on hLAM
In order to verify the differentiating capability of
UCMSCs in vitro on a more adapt biological support,
we seeded the cells on human liver acellular matrix.
Table 4 mRNA expression and albumin secretion at each
time-point
A) Kruskal-Wallis test
7 days 14 days 21 days 28 days
AFP 0.0493 NS 0.0491 NS
Alb 0.0332 0.0273 0.0391 0.0394
MTP nd nd nd nd
TDO nd nd nd nd
ALB secretion 0.0125 0.0231 0.0248 0.0210
B) Kruskal Wallis test followed by Bonferroni correction
7 days 14 days 21 days 28 days
Petri dishes
vs. hLAM
AFP 0.0153 NS 0.0138 0.0040
Alb NS 0.0014 0.0034 0.0010
MTP nd nd nd nd
TDO nd nd nd nd
Alb secr 0.0009 p< 0.0001 p< 0.0001 p< 0.0001
MatrigelTM
vs. hLAM
AFP NS NS NS NS
Alb 0.0039 NS NS NS
MTP nd nd nd nd
TDO nd nd nd nd
Alb secr NS p< 0.0001 p< 0.0001 p< 0.0001
Petri dishes
vs. MatrigelTM
AFP NS NS NS 0.0118
Alb 0.0003 0.0082 NS NS
MTP NS 0.0026 NS 0.0127
TDO p< 0.0001 p< 0.0001 p< 0.0001 p< 0.0001
Alb secr 0.0088 NS NS NS
(A) The Kruskal-Wallis test was used to evaluate the differences between the
three supports. (B) After Bonferroni correction p< 0.016 was assumed as
significant. nd: not detected; NS: not significant.Comparison between the
supports.
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croscopy (SEM) analyses showed that the matrix sections
obtained from human liver were completely decellularized
after a single treatment cycle. Masson’s trichrome staining
also confirms that the matrix retained its fibrillary compo-
nents after the treatment (data not shown).
qPCR analysis showed that the AFP and albumin
mRNA expression in UCMSCs seeded on hLAM either
in proliferative and differentiating medium remained
stable during the time. MTP and TDO mRNA were
never expressed in either proliferative or differentiating
conditions (Table 1).
Albumin detection in the supernatant of UCMSCs cul-
tured with the differentiating protocol showed a signifi-
cant increase during the time considered (¥p = 0.0006
z = 3.45), but the amount of protein secreted was always
significantly lower than with the other supports
(Tables 2–4). Both in proliferative and differentiative
conditions cells produced low and comparable levels of
urea [0.244 (0.202; 0.287) mM/104cells/day and 0.270
(0.230; 0.299) mM/104cells/day, respectively. *p =NS].
Comparison between supports: untreated plastic is most
suitable
To assess the differences between the three supports
considered in our study we performed a multiple com-
parison of the expression levels of each marker analyzed
and the albumin secretion at each time point. This ana-
lysis clearly suggested a difference between the supports
(Table 4A). The Kruskal-Wallis followed by Bonferroni
correction demonstrated that hLAM was the most un-
suitable support for the purpose of UCMSCs differenti-
ation. In fact, the pairwise comparison showed that the
AFP mRNA down-regulation and albumin mRNA up-
regulation were more marked in petri dishes. Further-
more, the albumin secretion was unequivocally stronger
when the cells were seeded on petri dishes or on Matri-
gelTM rather than seeded on hLAM. In addition, the
absence of any MTP and TDO mRNA, suggest that the
UCMSCs cultured on hLAM failed to reach the
hepatocyte-like phenotype (Table 4).
Pairwise comparison between petri dishes and Matri-
gel™ brings out that the AFP mRNA down-regulation
was more pronounced on petri dishes and reaching sig-
nificant levels at 28th day of differentiation (}p = 0.0118).
Finally, MTP mRNA up-regulation – which was al-
ways time-dependent - seemed to be more marked in
the cells seeded on untreated plastic support (¥p = 0.0021
vs. ¥p = 0.0122). The multiple comparison followed by
Bonferroni correction showed that MTP mRNA induc-
tion after 14 and 28 days was significantly greater on
petri dishes. Interestingly, TDO mRNA up-regulation
was verified exclusively when the cells were seeded on
untreated plastic support.Transplanted UCMSCs accelerate the recovery after
CCl4-induced liver injury
In order to evaluate the therapeutic potential of the
UCMSCs in an acute liver damage we transplanted them
into CCl4-treated mice. Considering their hepatocyte-like
phenotype and their capability to differentiate in hepatocyte-
like cells we transplanted undifferentiated UCMSCs.
CCl4 exposure induced confluent coagulative submas-
sive necrosis and disorganized the normal architecture of
parenchyma (Figure 4A). After 5 days from CCl4 adminis-
tration, the necrotic area was 31.27% of parenchyma, was
visible a conspicuous inflammatory infiltrate (Figure 4B-C
and higher magnification in Additional file 1: Figure S1)
and a large amount of activated Kupffer cells. At 8 day,
the necrotic areas were absent and totally replaced by














































Figure 4 CCl4-induced liver injury and liver recovery after
UCMSCs transplantation. (A) Haematoxylin and eosin stain. After
24 hours from CCl4 injection confluent coagulative submassive
necrosis affected 43.3% of the liver. The margins of representative
necrotic area (N) are indicated by arrows. (B) Haematoxylin and
eosin stain. After 5 days from CCl4 administration the necrotic area
(N, indicated by arrows) was still wide and there was a conspicuous
inflammatory infiltrate. After 8 days there were not necrotic areas
and numerous cellular clusters were evident (head arrows). See
Additional file 1: Figure S1 for higher magnification. UCMSCs
transplantation in CCl4-treated mice reduced the amount of
inflammatory cells and necrosis area after 5 days. Necrosis,
inflammatory recruited cells and cellular cluster were completely
absent after 8 days and histological pattern was becoming similar to
control healthy mice parenchyma (see Additional file 2: Figure S2).
(C) Necrosis quantification at day 5. Scale bar: 100 μm.
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mega macrophages and Kupffer cells. Indeed, these cells
were CD68 positive and were endowed with phagocytic
activity as demonstrated by PAS-D stain (Figure 5A-B).
UCMSCs transplantation in CCl4-treated mice
reduced the amount of inflammatory cells at day 5 and
the necrotic areas were about 17.2% of parenchyma.
Necrotic areas, inflammatory recruited cells and acti-
vated mega macrophages were completely absent after
8 days (Figures 4 and 5). Therefore histological pattern
developed characteristics similar to those of control





5 days 8 days
Figure 5 Identification of CD68 positive cells in liver. (A) CCl4-
treated mice. CCl4 induced Kupffer cells (representative cells indicated
by head arrows) activation at day 5. At day 8 were also evident
activated mega macrophages (arrows) that were organized to form
cellular clusters localized exclusively in necrotic areas.
(B) High magnification of CD68 positive cellular clusters (red square in A).
Mega macrophages were endowed with phagocytic activity as
demonstrated by PAS-D stain (right image). (C) UCMSCs transplantation
in CCl4-treated mice. The amount of CD68 positive cells was reduced at
day 5 compare to CCl4-trated mice. After 8 days there were few CD68
positive cells, as detected in control mice liver. (D) Control (PBS) mice
liver. Scale bars: 200 μm.
5 days 8 days
PBS                                      MSCs
A
B
Figure 6 Identification of human albumin positive cells in
transplanted mice liver. (A) Immunofluorescence analysis showed
positive cells for human albumin in livers of CCl4-treated mice that
had undergone UCMSCs transplantation both at day 5 and 8 from
the damage. (B) Mice livers from control groups did not show any











Figure 7 mRNAs expression of pro-inflammatory and anti-inflammato
regulation of mRNA coding for TNF-alpha, TGF-beta 1, IL-5 and IL-10. Following c
inflammatory cytokines mRNA up-regulation was significantly lower compared to
significantly higher compared to CCl4 group and returned to basal level after 8 d
bars represent Q1 and Q3, respectively. * Mann Whitney U test vs. PBS group; # M
p< 0.001.
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human albumin in livers of CCl4-treated mice that had
undergone UCMSCs transplantation both at 5 and 8 days
from the damage (Figure 6A). No cells were found in
transplanted mice without liver damage (Figure 6B).
Transplanted UCMSCs were able to reduce liver
inflammation and to inhibit stellate cell and
myofibroblasts activation
To confirm histological analysis, we evaluated the
inflammatory state quantifying mRNAs expression of
pro-inflammatory (TNF-alpha, IL-5 and TGF-beta 1)
and anti-inflammatory cytokines (IL-10) by qPCR. CCl4
administration induced significant up-regulation of
mRNA coding for all considered cytokines at both time
points. Following cell transplantation, both at 5 and
8 days from the damage, qPCR analysis showed that the
pro-inflammatory cytokines mRNA up-regulation was
significantly lower compared to mice that received only
CCl4, whereas IL-10 mRNA up-regulation at 5 days was
significantly higher compared to CCl4 group and










ry cytokines in vivo. CCl4 administration induced significant up-
ell transplantation, at both 5 and 8 days from the injury the pro-
mice that received only CCl4. IL-10 mRNA up-regulation at 5 days was
ays from the damage. Values represent median, negative and positive error
ann Whitney U test vs. CCl4 group *p< 0.05; ** or ## p< 0.01; *** or ###
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http://www.biomedcentral.com/1471-230X/12/88TGF-beta 1 modulation was correlated with activation/
deactivation of stellate cells and myofibroblasts. Immuno-
fluorescence showed that in CCl4-treated mice there was a





















Figure 8 Stellate cells and myofibroblasts activation in CCl4-treated m
alpha-SMA/desmin in CCl4-treated mice. A conspicuous number of alpha-SMA
them as stellate cells. Alpha-SMA single positive cells were myofibroblasts. At
alpha-SMA/desmin in CCl4-treated mice that had undergone UCMSCs transpl
vascular smooth muscle cells were detected. Few desmin positive cells were v
and quantity of double positive cells were comparable to alpha-SMA/desmin
white square represent a zoomed detail (see higher magnification on Additiopositive cells that significantly decreased during the time
[120.54 (117.90-122.13) and 102.16 (94.39-105.11) cells/
field at day 5 and 8 respectively; *p= 0.048]. To evaluate












ice with and without UCMSCs transplantation. (A) Co-staining
(smooth muscle actin) positive cells expressed also desmin identifying
day 8 both cellular types were significantly decreased. (B) Co-staining
antation. Both at day 5 and 8 no positive cells for alpha-SMA except
isible. (C) Co-staining alpha-SMA/nestin in CCl4-treated mice. Localization
positive cells confirming stellate cells identity. The images inside the
nal file 3: Figure S3). Scale bar: 100 μm.
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Desmin, an intermediate filament typical of contractile
cells, has been widely used as a "gold standard" for identify-
ing stellate cells in rodent liver [29]. At day 5, 80.55% of
alpha-SMA positive cells co-expressed desmin, decreasing
to 48.03% at day 8. To further confirm the identity of stel-
late cells, co-staining alpha-SMA/nestin was performed. It
is known that nestin, a class VI intermediate filament pro-
tein, is induced during stellate cells activation in rodent
liver [30]. Localization and quantity of alpha-SMA/nestin
double positive cells (77.27% and 53.34% at day 5 and 8, re-
spectively) were comparable to alpha-SMA/desmin positive
cells (Figure 8). Higher magnification of double positive
cells were showed in Additional file 3: Figure S3.
On the contrary, in UCMSCs transplanted mice there
were not positive cells for alpha-SMA except vascular
smooth muscle cells and few desmin and nestin positive
cells were visible (Figure 8).
UCMSCs influenced liver antioxidant enzyme activity
Antioxidant enzymes are considered to be the first line of
cellular defence that prevents cellular components from
oxidative damage. Among them, superoxide dismutase
(SOD) and catalase mutually function as important
enzymes in the elimination of ROS (reactive oxygen spe-
cies). A significant reduction in the activity of catalase was
observed in the liver tissue of the CCl4-intoxicated experi-
mental animals. Transplantation of UCMSCs alone
induced an increase of catalase activity (significant at day
5) compared to PBS (Phosphate Buffered Saline) group.
Transplantation of UCMSCs after CCl4 administration
increased catalase amount (reaching control values at day





Figure 9 Liver catalase activity. A significant reduction in the
activity of catalase was observed in the liver tissue of the CCl4-
intoxicated experimental animals. Transplantation of UCMSCs both
alone and after CCl4 administration, increased catalase activity
compared to respective control groups. The injection of oil alone
did not influence catalase activity. Values represent median, negative
and positive error bars represent Q1 and Q3, respectively. * Mann
Whitney U test vs. PBS group; # Mann Whitney U test vs. CCl4 group
* or # p< 0.05; **p< 0.01; ### p< 0.001.Discussion
Studies on stem cells and on their potential sources have
been intensified in recent years, given the promise of their
clinical application, especially in regenerative medicine [31].
Ethical problems regarding the use of human embryos
[5] and the neoplastic risks after their in vivo use [32] have
led to adult stem cells being considered a more acceptable
source. Bone marrow is a good source of adult stem cells
but the decrease in number of stem cells available with the
donor age and invasive procedure required to obtain the
cells are the major problems for their utilization [12,13].
Research has consequently turned towards finding alterna-
tive sources of MSCs, such as adipose tissue [14] and
foetal-derived tissues. Placenta, amniotic fluid and umbil-
ical cord indeed seem to contain undifferentiated cells,
due to their embryonal origin [15-18].
In this study we characterized a novel MSCs popula-
tion obtained from human UC (UCMSCs) and we have
induced their differentiation towards hepatic lineages
in vitro seeking the best cell support for this purpose.
Phenotypic analysis showed a profile compatible with
MSCs and the simultaneous high expression of CD166,
CD105 and CD73 demonstrated that our cells were a
novel MSCs population.
We found that these UCMSCs constitutively express
mRNA coding for specific hepatic markers such as AFP,
albumin and TDO. Then, for the first time, we unex-
pectedly demonstrated that undifferentiated UCMSCs
constitutively expressed mRNA coding for MTP, a trans-
fer protein localized in the endoplasmic reticulum of
mature hepatocytes and enterocytes; this protein cata-
lyses the transport of triglycerides, cholesteryl esters and
phospholipids [33].
We believe that these findings reinforce the conviction
that UCMSCs have a strong potential for differentiating
into hepatic-lineage cells in vitro.
In fact, when UCMSCs were stimulated to differentiate
towards a hepatic lineage, reached a hepatocyte-like
phenotype, amazingly, when seeded on a simple un-
treated plastic support.
Further confirmation comes from flow cytometric ana-
lysis on differentiated cells that demonstrated a conspicu-
ous drop in almost all the typical MSCs markers, such as
CD73, CD90, and CD105. The only exception was CD166
expression that was spontaneously lost in UCMSCs cul-
tured in proliferative medium while was maintained when
the cells were submitted to differentiation protocol. Inter-
estingly, CD29, another typical MSC marker, was
expressed higher in differentiated UCMSCs (79,4%) reach-
ing a level comparable with human hepatocytes [7].
The morphological features, loss of MSC phenotype,
gene expression changes, immunocytochemical staining,
albumin secretion, urea production and glycogen storage,
all suggested that these cells can grow and differentiate
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support, whereas cells seeded on 3D-supports showed a
minor (MatrigelTM) or negligible (hLAM) differentiation
capacity. Indeed, the data that unquestionably confirm our
assertions was on TDO mRNA modulation that was
found exclusively when the cells were differentiated on
petri dishes. Our data would indicate that hLAM is not a
suitable support for cell growth and hepatic differentiation
considering that the cells lost mRNA coding for MTP and
TDO after 7 days of culture and the supplementation with
hepatogenic differentiating factors did not influence the
basal AFP and albumin mRNA levels during 28 days of
stimulation. These findings suggest that, in our experi-
mental conditions, the coating afforded no advantage over
an untreated plastic support for the purpose of UCMSCs
hepatic differentiation; on the contrary, the simplest sup-
port seems to be the most suitable for this aim.
Taken together these results demonstrated that this
novel population is an ideal candidate for liver disease
treatment by cell therapy.
Mesenchymal stem cell transplantation has been
explored as a new clinical approach to repair injured tis-
sue. A growing number of studies have highlighted two
important aspects of MSC therapy: MSCs can modulate
T-cell mediated immunological responses [9,34] and fol-
lowing systemic administration these cells home to sites of
ischemia or injury, as was demonstrated in lung [22], heart
[23], kidney [24] and liver [35]. Several different MSC
sources have been evaluated for cell therapy in chronic
and acute liver diseases, such as bone marrow [36], amni-
otic fluid [37] and human umbilical cord blood [38,39].
On the contrary, UCMSCs have been exclusively consid-
ered for therapy in chronic liver diseases, such as fibrosis
and cirrhosis, and so far liver UCMSCs transplantation in
situ has been the unique administration route [40,41].
It has been documented that multipotent MSCs
synthesize a wide variety of growth factors and cyto-
kines, exerting a paracrine effect on local cellular dy-
namics [42]. Such trophic effects could be irrespective of
direct differentiation of transplanted cells into lineages
of the respective tissues as demonstrated in an ischemic
acute renal failure model [43]. The hepatogenic potential
and immunomodulatory activity of UCMSCs were fur-
ther investigated in this study employing systemic trans-
plantation in a murine model of acute liver injury
induced by a single administration of carbon tetrachlor-
ide, able to induce severe hepatic damage by generation
of oxidative stress and activation of immune cells [44].
In fact, so far the possibility of using human UCMSCs to
repair acute liver damage has not been evaluated and
they have been transplanted via systemic administration
by our group for the first time. MSCs were found to be
very resistant to ROS and induced a faster reduction of
oxidative stress in recipient mice [35]. For these reasons,we decided to transplant undifferentiated UCMSCs ra-
ther than pre-differentiated cells.
We transplanted UCMSCs after 24 hours from the
damage, when 40% of hepatic parenchyma was necrotic.
Cells were recruited in the injured tissue and then they
were able to engraft the liver (cells did not reach the
liver when transplanted in healthy mice) and to regulate
the inflammatory process. In fact in transplanted mice
as soon as 5 days after the CCl4 injection, the inflamma-
tory process was clearly attenuated, showing a moder-
ated infiltrate, a lower CD68 positivity, a lower pro-
inflammatory cytokines expression (primarily TNF-alpha
and TGF-beta 1) and a higher level of IL-10 gene ex-
pression compared to the CCl4 alone group.
At day 8 histological analysis of liver of CCl4 treated
mice showed the presence of cellular clusters that we
identified as mega macrophages and activated Kupffer
cells. In transplanted mice it was possible to identify ex-
clusively Kupffer cells only at day 5, whereas after 8 days
this activation phase was completely terminated. These
findings suggest that transplanted UCMSCs have anti-
inflammatory properties or are able to accelerate the
kinetic of inflammatory process, leading to liver recovery
in a shorter time.
During the pro-inflammatory process induced by
CCl4, jointly with Kupffer cells, stellate cells play a piv-
otal role. Immunofluorescence analysis showed that in
CCl4-treated mice there was a conspicuous number of
alpha-SMA positive cells. The most of these cells were
identified as activated stellate cells since they co-
expressed desmin and nestin. Alpha-SMA single positive
cells were another subpopulation of liver myofibroblasts.
Following cells transplantation there was no activation
of stellate cells, therefore, the anti-inflammatory activity
of UCMSCs was directed not only towards inflammatory
cells, including Kupffer cells but also against stellate cells
and myofibroblasts. TGF-beta 1 down-regulation in
transplanted mice confirmed our hypothesis.
The liver has several antioxidant enzymatic systems
such as superoxide dismutase, catalase and glutathione
peroxidase that play a fundamental role during physio-
logical and pathological ROS mediated oxidative stress.
We evaluated whether UCMSCs were able to ameliorate
hepatic damage also influencing the antioxidant systems,
measured by catalase activity within the liver. In CCl4
treated mice livers the activity of catalase was signifi-
cantly reduced compared with control groups. The en-
zyme was probably degraded or saturated to block CCl4-
induced massive free radical production. In presence of
mesenchymal stem cells catalase activity was higher after
8 days compared to CCl4 treated mice. These finding
suggested that UCMSCs reduced catalase consumption,
confirming that oxidative damage in transplanted mice
was nearly resolved.
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measured in the liver of UCMSCs transplanted mice
without any CCl4 induced damage (MSCs group) was
higher compared to PBS group. Therefore we speculate
that UCMSCs contribute to scavenging activity against
radicals by stimulating the activity of catalase, one of the
biological defence system of the liver.
In vivo experiments showed that unquestionably
UCMSCs were able to induce total liver recovery acting as
an adjuvant or modulating the physiologic defence sys-
tems. There is not a direct relationship between the num-
ber of cells that are found in the liver and the amazing
results in transplanted mice. It was demonstrated that
stem cells act through a dual mechanism: cell-to cell con-
tact and modulation mediated by soluble factors produced
by cells themselves. Our hypothesis is that cells have
immunomodulatory activity both at local level and before
homing to damaged tissue. It is possible that cells are able
to act also during their permanence in the bloodstream
and completing their action upon reaching the liver.
Increased catalase activity measured in MSCs group
demonstrated that cells were able to influence hepatic
antioxidant environment without liver engraftment.
Conclusions
Our results look promising for future application of
UCMSCs in regenerative medicine and clinical practice.
The chances of using such cells in this field are
increased by the simplicity and reproducibility with
which a significant number of cells can be obtained, by
the homogeneous features between different cellular pre-
parations that need not to undergo any sorting, by the
absence of immunogenicity (because UCMSCs are HLA-
DR-negative) and, most importantly, by the fact that
they carry no legal or ethical implications. Cell trans-
plantation is a practical procedure compared with organ
transplantation. It can be performed with much less risk
to the patient and much reduced cost for the healthcare
system. Furthermore, given the little invasiveness of sys-
temic administration, this method could be also applied
to patients who are severely ill and would not be able to
tolerate organ transplantation. We are aware that the
conveyance of our results into clinical practice would
need to be considered with caution because more infor-
mation is needed on these cells’ behavior in vivo before
any clinical applications can be hypothesized, but the
potential shown by our UCMSCs is undeniably fascinat-
ing and holds promise.
Methods
MSCs isolation from human umbilical cord
Umbilical cords from full-term deliveries were obtained
with the written informed consent of the mothers at the
Obstetrics and Gynecology Unit of Cittadella Hospitaland processed within 24 hours. They were collected in
accordance with the requirements of the local ethical
committee. The umbilical vessels were manually
removed and the jelly was minced to obtain small frag-
ments, which were plated in 100-mm petri dishes and
cultured with a proliferative medium [high-glucose Dul-
becco’s Modified Eagle’s Medium (DMEM) with stable
L-glutamine (Euroclone S.p.a., Milan, Italy), 100 U/mL
penicillin and 100 μg/mL streptomycin (Invitrogen Life
Technologies, Carlsbad, USA), and 20% FBS specific for
MSC cultures (Stem Cell Technologies Inc., USA)]. To
allow the cells to migrate from the tissue fragments, the
medium was first replaced after 5–7 days, and subse-
quently twice a week.
UCMSCs characterization
The UCMSCs were analyzed by flow cytometry for the
expression of the following antigens: CD14, CD29,
CD34, CD45, CD71, CD73, CD90, CD105, CD166, c-kit
and HLA-DR (Human Leukocyte Antigen-DR, a MHC
class II cell surface receptor). As a negative control, iso-
type control antibodies conjugated with FITC and RPE
(Santa Cruz Biotechnology, California) were used. The
cytofluorimetric analysis was performed with the MoFlo
High-Speed Cell Sorter (DAKO-Beckman Coulter, USA)
and the data were analyzed using Summit 4.3 software
(DAKO-Beckman Coulter, USA).
Mesenchymal stem cell features of UCMSCs isolated
were investigated by adipogenic and osteogenic differen-
tiation assay and their foetal origin was verified through
SRY (sex-determining region Y) gene analysis, as previ-
ously described by our group [21].
Human Liver Acellular Matrix (hLAM)
Surgical specimens from human livers were treated to ob-
tain hLAM according to Meezan et al. [45], with minor
modifications [26], on the day before each experiment.
The hLAM was analyzed by Masson trichrome stain-
ing (Bio-Optica, Milan, Italy) according to the manufac-
turer’s instructions and by scanning electron microscopy
(SEM) to assess its structure and fibrillary components.
In vitro hepatogenic differentiation on the three different
supports
UCMSCs seeded on untreated plastic supports were cul-
tured with hepatogenic differentiating medium consist-
ing of Iscove’s Modified Dulbecco’s Medium (IMDM)
(Euroclone S.p.a., Milan, Italy) supplemented with 15%
FBS, 100 U/mL penicillin and 100 μg/mL streptomycin,
1% L-glutamine, 10-7 M dexamethasone, 10 ng/ml oncos-
tatin M (Sigma-Aldrich, St. Louis, MO), 10 mg/ml ITS
supplement (Roche Applied Sciences, Italy), 20 ng/ml hep-
atocyte growth factor (HGF) and 100 ng/ml fibroblast
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cultured in proliferative medium were used as a control.
The media were changed twice a week and the cells were
collected at days 7, 14, 21 and 28 after induction. Immuno-
cytochemical analyses were performed for the hepatic mar-
ker AFP and albumin. The cultures were fixed with 2%
paraformaldehyde solution for 20 min at 4 °C and washed
in PBS. Immunocytochemical staining was done as previ-
ously reported [20]. UCMSCs were seeded on plastic sup-
ports coated with MatrigelTM (BD Biosciences Bedford,
MA, USA), diluted 1:10 with DMEM, and cultured for up
to 28 days, then stained as described above, or on hLAM
seeded on a 24-well plate coated with hLAM and cultured
as described previously up to 28 days.
qPCR
RNA isolated from UCMSCs at each time point was re-
verse-transcribed and amplified with the following pri-
mers: 5′-TGACTCCAGTAAACCCTGGT-3′ and 5-
AGAAATCTGCAATGACAGCC-3′ for AFP; 5′-ATCA
AGAAACAAACTGCACT-3′ and 5′-GCAGGTCTCCT
TATCGTCAG-3′ for albumin; 5′-CGTTCGGCATCTA
CTTACAGC-3′ and 5′-GTTCTCCTCCCCCTCGTC
AG-3′ for MTP; 5′-GGAGAAGAAAATGAACTGC
TAC-3′ and 5′-GGCTCTAAACCTGGAGT-3′ for
TDO; 5′-AGCAACAGGGTGGTGGAC-3′ and 5′-GT
GTGGTGGGGGACTGAG-3′ for GAPDH.
RNA isolated from mice liver was reverse-transcribed
and amplified with the following primers: 5’-TC
TTCTCATTCCTGCTTGTGG-3’ and 5’-GGTCTG
GGCCATAGAACTGA-3’ for TNF-alpha; 5′-AAGAGA
AGTGTGGCGAGGAG-3′ and 5′-CAGTTTTGTG
GGGTTTTTGC-3′ for IL-5; 5’-TGGAGCAACATGTG
GAACTC-3’ and 5’-GTCAGCAGCCGGTTACCA-3’ for
TGF-beta 1; 5’-CCAGTTTTACCTGGTAGAAGTG
ATG-3’ and 5’-TTTTCACAGGGGAGAAATCG-3’ for
IL-10; 5′-GATTACTGCTCTGGCTCCTA-3′ and 5′-TC
GTACTCCTGCTTGCTGAT-3′ for beta-actin.
After amplification, the data were analyzed using the sec-
ond-derivative algorithm. For each sample, the quantity of
specific hepatic marker mRNA was expressed as n-fold the
normalized amount of mRNA from undifferentiated cells.
Albumin detection
Albumin secretion in the culture medium was quantified
by ELISA according to the manufacturer’s instructions
(Alpha Diagnostic Intl. Texas, USA).
Urea assay
Urea concentration was quantified in supernatants col-
lected from differentiated and undifferentiated cells after
28 days. 24 hours before collection of supernatants NH4Cl
0.3 mM was added to the medium. Urea concentrationwas measured by a colorimetric assay, according to the
manufacturer’s instructions (Gentaur, Brussels, Belgium).Periodic Acid-Schiff Staining (PAS) and PAS-Diastase (PAS-D)
Cells were fixed using 4% paraformaldehyde for 10 min-
utes. After oxidizing in 0.5% periodic acid (Merck, NJ
USA) for 5 minutes, they were treated with Schiff ’s reagent
(Merck, NJ USA) for 15 minutes, then rinsed in water for
10 minutes and counterstained with haematoxylin.
For PAS-D the tissue-slides were incubated with dia-
stase solution (0.001 g/L in distilled water) in waterbath.
After washing, PAS stain standard procedure was per-
formed as described above.CCl4-induced liver injury and UCMSCs transplantation
Mice were divided randomly into five study groups with 6
animals per group. For acute CCl4-induced liver injury
eight- week-old male Balb/c mice were injected (i.p.) with a
single dose of CCl4 (0.75 ml/kg body weight of CCl4 dis-
solved in olive oil). The control mice received the same iso-
volumetric dose of olive oil as i.p. injections.
106 undifferentiated UCMSCs at passage 2 resuspended
in 150 μl of PBS were injected via tail vein 24 hours after
CCl4 injection. Control animals received the same volume
of PBS or UCMSCs alone. Animal care was in accordance
with our institutional guidelines.
Animals were sacrificed at day 5 and day 8 after CCl4 in-
jection; liver samples were collected and right lobe was
fixed in 4% formalin for 24 hours and embedded in paraf-
fin. The others lobes were stored at −80 °C until assayed.Histological analysis
Four-micrometer-thick liver sections were deparaffinized
and rehydrated. For histological examination the slides were
stained with haematoxylin and eosin. Morphometric ana-
lysis was performed measuring the percentage of necrotic
areas in 6 fields versus total section area. For immuno-
fluorescence analysis antigen retrieval was performed by
microwave-heating method in 0.01 mol/L citrate buffer
(pH 6). Slides were preincubated in goat serum (Sigma-
Aldrich, St. Louis, MO) at 1:25 dilution in PBS for 30
minutes and then were incubated in primary antibody
(monoclonal anti-alpha-SMA; monoclonal anti-human
albumin, polyclonal anti-desmin and polyclonal anti-
nestin, Sigma-Aldrich, St. Louis, MO) at a dilution from
1:100 to 1:2000 for 1 hour. The secondary antibody was a
FITC-conjugated anti-mouse (Sigma-Aldrich, St. Louis,
MO) and rhodamine-conjugated anti-rabbit (Santa Cruz
Biotech., CA) at a dilution of 1:160 for 45 minutes. The
section was counterstained with the nuclear marker DAPI
(Vector Laboratories). Sections were imaged on Leica SP5
Confocal Microscope.
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dom fields (100x) and expressed as cells for field.
For immunohistochemistry sections were stained with
anti-mouse CD68 antibody (Sigma-Aldrich, St. Louis, MO).
Detection was performed after incubating the sections with
horseradish peroxidase–conjugated anti-mouse antibody.
Peroxidase activity was revealed by 5-minute exposure to
diaminobenzidine (Sigma-Aldrich, St. Louis, MO). After
washing, preparations were counterstained with Mayer’s
haematoxylin for 10 minutes and mounted for analysis.
Determination of catalase activity
Liver homogenates were prepared in phosphate buffer con-
taining 0.5% triton (pH=7.4). Samples were centrifuged at
12,000 x g for 30 min at 4 °C. The supernatant was col-
lected and protein concentration was estimated by BCATM
protein assay kit (Pierce Company, Rockford, IL USA).
Catalase activity was determined by measuring the expo-
nential disappearance of H2O2 at 240 nm and expressed in
units/mg of protein as described by Aebi [46].
Statistical analyses
Data are given as median (Quartile 1; Quartile 3). The non-
parametric Mann–Whitney U-test was used to assess differ-
ences between differentiated and control cells; time trends
were evaluated using the Cuzick’s test based on Wilcoxon’s
approach. Kruskal-Wallis test was used for multiple com-
parisons followed by the post hoc Bonferroni correction.
A p-value lower than 0.05 was assumed to indicate a sig-
nificant difference (Bonferroni-adjusted at 0.016). Data
analyses were performed with SPSS and StatsDirect.
Additional files
Additional file 1: Figure S1. Characterization of CCl4-induced liver injury.
Haematoxylin and eosin stain. After 5 days from CCl4 administration there
was a conspicuous cellular inflammatory infiltrate. After 8 days numerous
cellular clusters were evident. Scale bar: 100 μm.
Additional file 2: Figure S2. Liver histology in mice control groups.
Haematoxylin and eosin stain. Mice livers from control groups did not show
any parenchymal abnormality. Scale bar: 100 μm.
Additional file 3: Figure S3. Stellate cells and myofibroblasts activation in
CCl4-treated mice. Double positive alpha-SMA/desmin and alpha-SMA
/nestin cells represented activated stellate cells in livers of CCl4-treated mice.
Alpha-SMA (green) single positive cells were myofibroblasts. Scale bar:
100 μm.
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